Taysha Gene Therapies, Inc. (TSHA) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -40.88M | -26.72M | -24.17M | -20.18M | -22.02M | -18.31M | -21.61M | -21.5M | -19.8M | -16.12M | -17.95M | -18.77M |
| Operating CF Margin % | - | -487.18% | - | -1016.21% | -956.56% | -905.44% | -1208.89% | -1933.81% | -580.42% | -447.2% | -378.19% | -783.59% |
| Operating CF Growth % | -85.64% | -45.96% | -11.8% | 6.15% | -11.22% | -13.59% | -20.42% | -14.58% | 1.92% | -212.89% | 37.7% | 43.73% |
| Net Income | -42.41M | -27.85M | -32.73M | -26.88M | -21.53M | -18.79M | -25.52M | -20.93M | -24.06M | 47.74M | -117.09M | -24.6M |
| Depreciation & Amortization | 295K | 299K | 433K | 277K | 283K | 304K | 294K | 322K | 325K | 366K | 331K | 343K |
| Stock-Based Compensation | 0 | 3.53M | 3.29M | 3.19M | 3.29M | 3.22M | 3.36M | 3.33M | 3.2M | 1.97M | 2.04M | 2.22M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3.93M | 101.07M | 0 |
| Other Non-Cash Items | 5.89M | 4.37M | -1.13M | 1.01M | 488K | -442K | 6.14M | 52K | 442K | -57.41M | 3.07M | 4.06M |
| Working Capital Changes | -4.65M | -7.07M | 5.98M | 2.23M | -4.56M | -2.6M | -5.88M | -4.28M | 298K | -4.85M | -7.37M | -796K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.29M | -2.13M | 0 | 3M | 923K | -1.5M | -3.78M | -1.61M | 3.98M | -1.23M | -3.19M | 1.76M |
| Cash from Investing | -3.02M | -247K | -48K | 62K | -371K | 13K | -35K | -201K | -140K | -10K | -3.49M | 48K |
| Capital Expenditures | -3.02M | -250K | -108K | -2K | -378K | 2K | -35K | -201K | -140K | -17K | -3.5M | 48K |
| CapEx % of Revenue | - | 4.56% | - | 0.1% | 16.42% | 0.1% | 1.96% | 18.08% | 4.1% | 0.47% | 73.75% | 2% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 3K | 60K | 64K | 7K | 11K | 0 | 0 | 0 | 7K | 10K | 0 |
| Cash from Financing | 711K | 49.56M | 8.8M | 216.29M | -52K | -357K | 6.59M | 70.47M | -22K | -4.25M | 140.63M | 377K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3.85M | 0 | 0 |
| Equity Issued (Net) | 692K | 49.61M | -173K | 216.17M | 75K | -360K | 6.66M | 70.48M | 0 | -423K | 140.71M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | -173K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 19K | -57K | 8.97M | 118K | -127K | 3K | -64K | -13K | -22K | 24K | -79K | 377K |
| Net Change in Cash | -43.19M | 22.59M | -15.42M | 196.17M | -22.44M | -18.65M | -15.05M | 48.76M | -19.96M | -20.38M | 119.19M | -18.34M |
| Free Cash Flow | -40.9M | -26.97M | -24.27M | -20.18M | -22.4M | -18.31M | -21.65M | -21.7M | -19.94M | -16.13M | -21.45M | -18.72M |
| FCF Margin % | - | -491.74% | - | -1016.31% | -972.98% | -905.34% | -1210.85% | -1951.89% | -584.52% | -447.67% | -451.94% | -781.59% |
| FCF Growth % | -82.61% | -47.34% | -12.12% | 7.01% | -12.34% | -13.46% | -0.94% | -15.95% | 17.22% | -234.81% | 32.61% | 54.86% |
| FCF per Share | -0.11 | -0.08 | -0.07 | -0.07 | -0.08 | -0.09 | -0.08 | -0.09 | -0.09 | -0.09 | -0.17 | -0.29 |
| FCF Conversion (FCF/Net Income) | 0.96x | 0.96x | 0.74x | 0.75x | 1.02x | 0.97x | 0.85x | 1.03x | 0.82x | -0.34x | 0.15x | 0.76x |
| Interest Paid | 0 | 0 | 1.36M | 0 | 1.29M | 1.3M | 1.32M | 1.33M | 1.33M | 1.29M | 1.27M | 1.27M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |